Human antibodies to fight ebola viruses discovered

Image
IANS New York
Last Updated : May 19 2017 | 1:48 PM IST

In a first, scientists led by one of Indian-origin have discovered natural human antibodies that can neutralise and protect animals against three virulent ebola viruses, an advance that could lead to vaccines against the deadly disease.

The broadly neutralising natural human antibodies were discovered in the blood of a survivor of the 2013-16 ebola outbreak in Western Africa, which caused more than 11,000 deaths and infected over 29,000 people.

The blood was found to contain remarkable antibodies that block not just one strain of Ebola from infecting animal cells, but all five known strains -- Zaire, Bundibugyo, Sudan, Reston and Tai Forest, the researchers said.

Our discovery and characterisation of broadly neutralising human antibodies is an important step toward a single therapy that could treat or prevent infection caused by any known ebolavirus, said Kartik Chandran, professor at Albert Einstein College of Medicine, New York.

Previously, monoclonal antibodies -- which bind to and neutralide specific pathogens and toxins -- emerged as one of the most promising treatments for Ebola patients. However, the therapy targetted just one of the specific ebola virus and could not work against the others.

In the study, published in the journal Cell, the team found that two of the 349 monoclonal antibodies -- ADI-15878 and ADI-15742 -- from the Ebola survivor, potently neutralised infection by all five known ebolaviruses in tissue culture.

Both the antibodies were able to protect animals (mice and ferrets) that had been exposed to a lethal dose of the three major agents: ebola virus, Bundibugyo virus and Sudan virus.

The study also pinpointed the human genes that are the likely source of the immune cells that produce the two antibodies.

"We'd like to synthesise vaccine immunogens [proteins that trigger antibody production] that can elicit the same types of broadly protective antibodies in people," Chandran added.

--IANS

rt/ksk/vt

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 19 2017 | 1:38 PM IST

Next Story